A risk benefit assessment of HIV protease inhibitors

Drug Safety

Volumn 20, Issue 4, 1999, Pages 299-321

  Moyle, Graeme J ^a   Gazzard, Brian G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATORVASTATIN; CD4 ANTIGEN; DELAVIRDINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASTHENIA; BLEEDING; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG TOXICITY; FATIGUE; FLATULENCE; HEART INFARCTION; HEMOLYSIS; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; INSOMNIA; LIPODYSTROPHY; LYMPHOCYTE COUNT; MORBIDITY; MORTALITY; MYALGIA; NEPHROLITHIASIS; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVIEW; RISK BENEFIT ANALYSIS; VIRUS LOAD; XEROSTOMIA;

HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; RISK ASSESSMENT;

EID: 0032891067     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199920040-00002     Document Type: Review

References (94)

1. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection - a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941-9
2. Cooper DA, Gatell JM, Kroon S, et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 1993; 329: 297-303
3. Concorde Coordinating Committee. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-81
4. Domingo P, Guariola JM, Ris R, et al. The impact of new anti-retroviral regimens on HIV-associated hospital admissions and deaths. AIDS 1998; 12: 592-3
5. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection. Pharmacoeconomics 1996; 10: 109-13
6. Domingo P, Guariola JM, Ris R, et al. The impact of new anti-retroviral regimens on HIV-associated hospital admissions and deaths. AIDS 1998; 12: 592-3
7. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. JAMA 1998; 280: 78-86
8. BHIVA Guidelines co-ordinating committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1086-92
9. Gazzard B, Moyle G on behalf of the BHIVA Guidelines Writing Committee. 1998 Revision to the British HIV Association Guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352: 314-0
10. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33
11. Stellbrink H-J on behalf of the Invirase International Phase II Trial (SV-14604) Group. Clinical and survival benefit of saquinavir (SQV) in combination with zalcitabine (ddC) and zidovudine (ZDV) in untreated/minimally treated HIV-infected patients [abstract]. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection; 1997 Oct 11-15: Hamburg
12. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998; 351: 543-9
13. Moyle GJ, Gazzard BG, Cooper DA, et al. Antiretroviral therapy for HIV infection: a knowledge-based approach to drug selection and use. Drugs 1998; 55: 383-404
14. Cao Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency type I infection. N Engl J Med 1995; 332: 201-8
15. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subject with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332: 209-16
16. Craib KJP, Strathdee SA, Hogg RS, et al. Serum levels of human immunodeficiency virus type I(HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection. J Infect Dis 1997; 176: 798-800
17. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-54
18. 2-microglobulin. J Infect Dis 1997; 176: 1161-7
19. de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127: 882-90
20. Lenderking WR, Gelber RD, Cotton DJ, et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 1994; 330: 738-4
21. Revicki DA, Moyle G, Stellbrink H-J, et al. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavirzidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 counts between 50 and 350 per cubic millimeter. AIDS. In press
22. Cohen C, Revicki DA, Nabulsi A, et al. and the Advanced HIV Disease Ritonavir Study Group. A randomised trial of the effect of Ritonavir in maintaining quality of life in advanced disease. AIDS 1998; 12: 1495-1502
23. Singh N, Squier C, Sivek C, Wagener M, et al. Determinants of adherence with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing adherence. AIDS Care 1996; 8 (3): 261-9
24. Vanhove GF, Schapiro JM, Winters MA, et al. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 1996; 276; 1955-6
25. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401-8
26. Moyle GJ. Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice. Exp Opin Invest Drugs 1997; 6: 943-64
27. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-300
28. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-6
29. Pantaleo G. How immune-based interventions can change HIV therapy. Nature Med 1997; 3: 483-6
30. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997; 3: 533-40
31. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus infected patients. J Infect Dis 1998; 117: 1080-3
32. Gill J, Moyle G, Nelson M. Discontinuation of MAC prophylaxis in patients with a rise in CD4 count following highly active anti-retroviral therapy (HAART). AIDS 1998; 12: 680
33. Polis MA, Schrager L, Yoder C, et al. Virologic, immunologic and histologic responses to a 4-drug combination therapy in antiretroviral naïve HIV infected persons. 5th Conference on Retroviruses and Opportunistic Infections [abstract]. Chicago; 1998 Feb 1-5; 394, 152
34. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and disease staging. J Clin Invest 1989; 84: 1892-9
35. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995; 267: 483-9
36. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-91
37. Staszewski S, Morales-Ramirez J, Tashima K, et al. A phase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV)+indinavir (INV) versus EFV+zidovudine (ZDV)+lamivudine (3TC) versus IDV+ZDV+3TC at 24 weeks [Study DMP266-006] [abstract 22336]. 12th World AIDS Conference; 1998 Jun 28-Jul 3: Geneva
38. Foster RH, Faulds, D. Abacavir. Drugs 1998; 55: 729-36
39. Hammer S, Katzenstein D, Hughes M, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081-90
40. CAESAR coordinating committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413-21
41. Bartlett JA, Benoit SL, Johnson VA, et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125: 161-72
42. Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, ZDV-experienced patients. A randomised, double-blind, controlled trial. Ann Intern Med 1997; 126: 355-63
43. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 1998; 19 (6): 484-94
44. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with Human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 743-39
45. Moyle GJ, Youle M, Higgs C, et al. Safety, pharmacokinetics and antiretroviral activity of the potent, specific HIV protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in HIV-infected patients. J Clin Pharmacol 1998; 38: 736-43
46. Razzeca K, Odenheimer S, Davis M, et al. The treatment of nelfinavir (NFV) induced diarrhoea [abstract 12383]. 12th World AIDS Conference; 1998 Jun 28-Jul 3: Geneva
47. Petersen A, Johnson M, Clendennin N, et al. Comparison of BID and TID dosing of nelfinavir (NFV) in combination with stavudine (stavudine) and lamivudine (3TC): an interim look [abstract 373]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5: Chicago
48. Moyle G on behalf of the SPICE study team. Study of protease inhibitor combination in Europe (SPICE): saquinavir soft gelatin capsule (SQV-SGC) plus nelfinavir (NFV) in HIV infected individuals [abstract 12222]. 12th World AIDS Conference; 1998 Jun 28-Jul 3: Geneva
49. Reijers MHE, Weverling GJ, Jurriaans S, et al. Viral suppression with maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: amsterdam duration of antiretroviral medication (ADAM) study. Lancet 1998; 352: 185-90
50. Gill MJ, on behalf of the NV15182 study team. Safety profile of soft gelatin capsule of saquinavir in combination with nucleosides in a broad patient population. AIDS 1998; 12: 1400-2
51. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F8
52. Lo JC, Mulligan K, Tai VW, et al. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998; 351: 867-70
53. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation with use of indinavir. Lancet 1998; 351: 871-5
54. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12: F37-F9
55. Herry I, Bernard L, de Truchis P. Hypertrophy of the breasts in a patient treated with indinavir. Clin Infect Dis 1997; 25: 937-8
56. Toma E, Therrien R. Gynaecomastia during indinavir antiretroviral therapy in HIV infection. AIDS 1998; 12: 681-2
57. Dever LL, Oruwari PA, O'Donavan, et al. Hyperglycaemia associated with protease inhibitors in HIV-infected patients [abstract LB-8]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1: Toronto, Canada
58. Carr A, Cooper D, Thorisdottir A, et al. Prevalence and severity of protease inhibitor (PI) induced lipodystrophy and insulin resistance [abstract 12462]. 12th World AIDS Conference; 1998 Jun 28-Jul 3: Geneva
59. Caldwell R, Rothstein A, Allmon C, et al. Evaluation of protease inhibitor associated hyperglycaemia in a University-based HIV clinic [abstract 12395]. 12th World AIDS Conference; 1998 Jun 28-Jul 3: Geneva
60. Sullivan AK, Feher MD, Nelson MR, et al. Marked hypertriglyceridaemia associated with ritonavir therapy. AIDS 1998; 12: 1393-4
61. Chang E, Deleo M, Liu YT, et al. The effects of antiretroviral protease inhibitors (PIs) on serum lipids and glucose in HIV-infected persons [abstract 12381]. 12th World AIDS Conference; 1998 Jun 28-Jul 3: Geneva
62. Nelson MR, Moyle G, Newell A, et al. The incidence of hyperlipidaemia with protease inhibitors [abstract 1-87]: 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998 Sep 24-27: San Diego: 389
63. Rothstein AM, Caldwell RD, Allmaon C, et al. Investigation of protease inhibitor-associated hypercholesterolaemia in a University-based HIV clinic [abstract I-91]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 1998 Sep 24-27: San Diego: 390
64. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351: 1328
65. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998; 352: 1881-3
66. Prazuck T, Semaille C, Roques S. Fatal haemolysis in an AIDS patient treated with indinavir. AIDS 1998; 12: 531-3
67. HIV protease inhibitors and patients with haemophilia. Letter to healthcare providers. US Food and Drug Administration; July 17 1996
68. Stanworth SJ, Bolton MJ, Hay CRM, et al. Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors. Haemophilia 1998; 4: 109-14
69. Bonfanti P, Capetti A, Riva P, et al. Hypersensitivity reactions during antiretroviral regimens with protease inhibitors. AIDS 1997; 11: 1301-2
70. Rijnders B, Kooman J. Severe allergic reaction after repeated exposure to indinavir. Clin Infect Dis 1998; 26: 523-4
71. Murphy M, Armstrong D, Sepkowitz KA, et al. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-protease inhibitor. AIDS 1997; 11: 261-2
72. Hicks CB, Myers SA, Giner J. Resolution of intractable molluscum contagiosum in a human immunodeficiency virus infected patient after institution of antiretroviral therapy with ritonavir. Clin Infect Dis 1997; 24: 1023-5
73. Jacobsen MA, Zrgans M, Pavan PR, et al. Cytomegalovirus retinilis after initiation of highly active antiretroviral therapy. Lancet 1997; 349: 1443-5
74. Nussenblatt RB, Lane HC. Human immunodeficiency virus disease: changing patterns of intraocular inflammation. Am J Ophthalmol 1998; 125: 374-82
75. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351: 252-5
76. Kopp JB, Miller KD, Mican JAM, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127: 119-25
77. Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy. N Engl J Med 1997; 336: 138-9
78. Bach MC, Godofsky EW. Indinavir nephrolithiasis in warm climates. J AIDS 1997; 14: 296-97
79. Berns JS, Cohen RM, Silverman M, et al. Acute renal failure due to indinavir crystalluria and nephrolithiasis: a report of 2 cases. Am J Kidney Dis 1997; 30: 558-60
80. Reitsma WJ. Fever, erythroderma, abdominal pain and renal failure following initiation of indinavir therapy. Clin Infect Dis 1997; 25: 1268-9
81. Asher DP, Lucy MD. Indinavir sulphate renal toxicity in a paediatric haemophiliac with HIV infection. Ann Pharmacother 1997; 31: 1146-9
82. Chen SCA, Nankivell BJ, Dwyer DE. Indinavir-induced renal failure. AIDS 1998; 12: 440-1
83. Grunke M, Valerius T, Manger B, et al. Renal dysfunction in a HIV-infected patient who was treated with indinavir. Clin Infect Dis 1997; 25: 1270-1
84. Juerissen FJF, Schneider MME, Borleffs JCC. Is the combination of hepatitis and indinavir potentially dangerous? AIDS 1998; 12: 441-2
85. Merck Sharpe & Dohme. European Summary of Product Characteristics for Indinavir. White House Station (NJ), USA
86. Casada JL, Perez-Elias MJ, Antlea A. Risk factors for ritonavir intolerance and outcome after change to indinavir. AIDS 1998; 12: 335-6
87. Van Hove G, Arribas JR, Lazzarin A, et al. Effect of dose escalation on the safety, tolerability and efficacy of ritonavir [abstract 12283]. 12th World AIDS Conference; 1998 Jun 28-Jul 3: Geneva
88. Arribas JR, Ibanez C, Ruiz-Antoran B, et al. Acute hepatitis in HIV-infected patients during ritonavir therapy. AIDS 1998; 12: 1722-4
89. Haubrich R, Lalezari J, Follansbee SE, et al. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther 1998; 3: 33-42
90. Markowitz M, Conant M, Hurley A, et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998; 117: 1533-40
91. Moyle GJ. The role of combinations of HIV protease inhibitors in management of persons with HIV infection. Exp Opin Invest Drugs 1998; 7: 413-26
92. Eisen S, Miller D, Woodward R, et al. The effect of prescribed daily dose frequency on patient medication compliance. Ann Intern Med 1990; 150; 1881-4
93. Rudd P, Ahmed S, Zachery V, et al. Improved compliance measures: applications in an ambulatory hypertensive trial. Clin Pharmacol Ther 1990; 48: 676-85
94. Walsh JC, Dalton M, Gill J, et al. Adherence to highly active antiretroviral therapy (HAART) [abstract I-171] 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 1998 Sep 24-27: San Diego: 419